Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
AssigneeNikang Therapeutics, Inc.
InventorsCharles M. Cook, Jiping Fu, Yigang He, Yan Lou, Rongzhen Chen, Yan Dong
Life of this patent
Estimating the term…
Abstract
The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.
Claims34
An amine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, wherein the amine is:
- (i) NHR1R2 where (1) R1 is hydrogen and R2 is C2-C12 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl;
- (2) R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl and R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl;
- or (3) R1 and R2 together with the nitrogen atom to which they are attached form cyclylamine;
- or
- (ii) R3R4N—(CH2)n—NR5R6 where n is an integer selected from 1 to 6 and R3, R4, R5, and R6 are independently H, C1-C6 alkyl, or C3-C7 cycloalkyl.
A crystalline form of a diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, designated as Form B polymorph, having an X-ray powder diffraction pattern comprising peaks at angular positions 13.8 and 21.3, wherein the angular positions may vary by +/−0.2° 2θ as measured by X-ray powder diffraction at ambient temperature using (Cu Kα) an X-ray wavelength of 1.5406 Å.
A process of preparing an amine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile)-benzonitrile, wherein the amine is:
- (i) NHR1R2 where (1) R1 is hydrogen and R2 is C2-C12 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl;
- (2) R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl and R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, or C3-C7 cycloalkyl-C1-6 alkyl;
- or (3) R1 and R2 together with the nitrogen atom to which they are attached form cyclylamine;
- or
- (ii) R3R4N—(CH2)n—NR5R6 where n is an integer selected from 1 to 6 and R3, R4, R5, and R6 are independently H, C1-C6 alkyl or C3-C7 cycloalkyl, comprising:
- (a1) contacting 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile with the amine NHR1R2 or R3R4—N—(CH2)n—R5R6 where R1 and R2 are as defined in (i), and R3, R4, R5, R6, and n are as defined in (ii), in the presence or absence of one or more suitable organic solvents to provide a mixture containing the amine solvate;
- (b1) optionally adding (i) one or more anti-solvent and/or (ii) a solid crystalline seed of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, or a solid crystalline seed of the amine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, or a combination thereof, to the mixture of Step (a1) to precipitate the amine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile;
- and
- (c1) isolating the precipitate of Step (b1) to obtain a solid amine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile.
A process of preparing crystalline Form B polymorph of a diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile having an X-ray powder diffraction pattern comprising peaks at angular positions 13.8 and 21.3, wherein the angular positions may vary by +/−0.2° 2θ as measured by X-ray powder diffraction at ambient temperature using (Cu Kα) an X-ray wavelength of 1.5406 Å, comprising:
- (a2) contacting 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile with diethylamine, in the presence or absence of one or more suitable organic solvents to provide a mixture containing diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile;
- (b2) adding (i) one or more anti-solvent and/or (ii) a crystalline seed of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, or a solid crystalline seed of the diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, or a combination thereof, to the mixture of Step (a2) to precipitate the crystalline Form B polymorph of the diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile;
- and
- (c2) isolating the crystalline Form B polymorph of the diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile.
A solid composition comprising a diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile and 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, wherein the % weight ratio of the diethylamine solvate of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile to 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile in the composition is from about 1:9 to about 1:0.001.
Dependencies are inferred from the claim text.